Financial News

RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform

RenovoRx Inc (NASDAQ: RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an overview of the lead candidate product RenovoGem that he has presented to the Congress, before going on to explain where the product is in its development cycle. He says the product has met with "a lot of enthusiasm" so far and reveals his hopes of getting early approval from the FDA "next year or early in 2025."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.19
+2.24 (1.03%)
AAPL  259.09
+0.64 (0.25%)
AMD  232.85
+2.62 (1.14%)
BAC  51.45
+0.35 (0.69%)
GOOG  255.18
+2.65 (1.05%)
META  740.00
+6.59 (0.90%)
MSFT  522.65
+2.11 (0.41%)
NVDA  182.06
+1.78 (0.99%)
ORCL  280.38
+7.72 (2.83%)
TSLA  429.16
-9.81 (-2.23%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback